Back to top

vaccines: Archive

Zacks Equity Research

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.

MRNANegative Net Change MRKNegative Net Change ABUSPositive Net Change

Sundeep Ganoria

Buy Moderna Stock Before Q3 Earnings? Here's What to Know

MRNA's Q3 earnings are expected to arrive amid a 652% stock rally, premium valuation and promising cancer therapy data. Should investors buy, sell or hold?

MRNANegative Net Change GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change

Sundeep Ganoria

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

GSKNegative Net Change MRNANegative Net Change PFEPositive Net Change MRKNegative Net Change